02172 MICROPORT NEURO
- 9.290
- -0.020-0.21%
MICROPORT NEURO News
Microport NeuroTech Swings to Profit in 2023 as Revenue Jumps 22%
Microport NeuroTech (HKG:2172) recorded an attributable profit of 145.5 million yuan in 2023, versus an attributable loss of 21.8 million yuan in 2022, according to the company's annual report filed w
微創腦科學：2023年度報告
Is There An Opportunity With MicroPort NeuroTech Limited's (HKG:2172) 43% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, MicroPort NeuroTech fair value estimate is HK$16.08 MicroPort NeuroTech's HK$9.15 share price signals that it might be 43% undervalued Ana
[Broker Focus] Zheshang Securities maintains minimally invasive brain science (02172) holdings” rating indicates that its revenue and profit are expected to increase rapidly
Jinwu Financial News | According to Zheshang Securities Research, Minimally Invasive Brain Science (02172) had revenue of 666 million yuan in 2023, an increase of 21.6% over the previous year, and net profit of 135 million yuan, turning losses into profits and growing strongly over the previous year. The bank believes that as the company continues to release new products, high revenue and profit growth can be expected in 2024. According to the bank, in 2023, the company's gross profit margin was 76.9%, an increase of 5.1 pct over the previous year, mainly due to supply chain improvements. In 2023, the company completed more than 60 supply chain improvements and upgrades, and the localization rate of raw materials reached more than 90%, with remarkable cost reduction and efficiency effects; 202
The results for the full year of 2023 were announced. What was the performance of innovative medical device companies under the collection test?
Hengqiang, the strongest in innovative medical devices
MICROPORT NEURO To Go Ex-Dividend On June 28th, 2024 With 0.11 HKD Dividend Per Share
March 30th - $MICROPORT NEURO(02172.HK)$ is trading ex-dividend on June 28th, 2024. Shareholders of record on July 2nd, 2024 will receive 0.11 HKD dividend per share on August 22nd, 2024. The ex-d
Minimally Invasive Brain Science (02172) grants 2.191 million share options
Minimally Invasive Brain Science (02172) issued an announcement. On March 28, 2024, the company decided to comply with the company's 20...
Minimally Invasive Brain Science (02172.HK) suggests changing the English name to “MicroPort NeuroScientific Corporation”
GLONGHUI March 27 | Minimally Invasive Brain Science (02172.HK) issued an announcement. The company's board of directors proposed changing the company's English name from “MicroPort NeuroTech Limited” to “MicroPort NeuroScientific Corporation”. The company's Chinese name remains unchanged.
Minimally Invasive Brain Science (02172) will pay a final dividend of HK$0.11 per share on August 22
Minimally Invasive Brain Science (02172) issued an announcement which will be distributed on August 22, 2024 until December 2023...
Minimally Invasive Brain Science (02172) announced annual results, profit attributable to shareholders of 146 million yuan, and turned a year-on-year loss into a profit
According to Zhitong Finance App News, Minimally Invasive Brain Science (02172) announced its annual results for the year ended December 31, 2023. The group achieved revenue of 666 million yuan (RMB, same below), an increase of 21.61% over the same period last year; profit attributable to shareholders was 146 million yuan, and losses due to shareholders were 21.755 million yuan during the same period last year, turning a loss into profit from the previous year; basic profit of 0.25 yuan per share; it is proposed to distribute a final dividend of HK$0.11 per share. According to the announcement, the increase in revenue was mainly due to a variety of market-leading products (including Tubridge blood flow guided dense mesh stents and Bridge vertebral artery
MICROPORT NEURO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Minimally Invasive Brain Science (02172.HK) plans to hold a board meeting on March 27 to approve annual results
Gelonghui, March 15, 丨 Minimally Invasive Brain Science (02172.HK) announced that the company would like to hold a board meeting on March 27, 2024 (Wednesday) to consider and approve the Group's annual results and announcements for the year ended 31 December 2023, and to consider the payment of a final dividend (if any), and to deal with other matters.
MICROPORT NEURO: DATE OF BOARD MEETING
Is The Market Rewarding MicroPort NeuroTech Limited (HKG:2172) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
MicroPort NeuroTech (HKG:2172) has had a rough three months with its share price down 20%. It is possible that the markets have ignored the company's differing financials and decided to lean-in to t
Changes in Hong Kong stocks | Minimally Invasive Brain Science (02172) rose more than 5%, leading medical device stock institutions optimistic about the future prospects of overseas expansion of domestic medical devices
The increase in medical device stocks increased in the afternoon. As of press release, Minimally Invasive Brain Science (02172) rose 6.46% to HK$9.4; Chunli Healthcare (01858) rose 4.61% to HK$9.31; Haohai Biotech (06826) rose 3.71% to HK$34.95; and Novi Health (06606) rose 2.35% to HK$18.28.
Investors Met With Slowing Returns on Capital At MicroPort NeuroTech (HKG:2172)
What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a perfect world, we'd like to see a company investing more capital into its busine
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Changes in Hong Kong stocks | Minimally Invasive Brain Science (02172) rose more than 4% and is expected to increase annual adjusted net profit by at least 36% year on year
Minimally Invasive Brain Science (02172) rose 7% after yesterday's profit, and today it's up more than 4%. As of press release, it rose 4.09% to HK$10.68, with a turnover of HK$10.139,500.
[Company Yingxi] Minimally Invasive Brain Science (02172) is expected to turn a loss into a profit last year
Jinwu Financial News | Minimally Invasive Brain Science (02172) is expected to record adjusted net profit of not less than RMB 178 million (same below) for the year ending the end of December 2023, an increase of at least 36% over the year ended December 2022. Compared with the net loss of 24.68 million yuan recorded last year, the Group is expected to turn net profit into profit and grow strongly. According to the announcement, the sharp increase in profit expectations is mainly due to various market-share leading products continuing to explore the market and achieve significant revenue growth; the newly approved products in 2022 accelerated hospital access and contributed to the increase in the Group's revenue; and through execution of supply
MicroPort NeuroTech: Higher Sales of Medical Products in New Markets Supported Results
MicroPort NeuroTech: Higher Sales of Medical Products in New Markets Supported Results
Analysis
Price Target
No Data
